Clinical trials: cyclosporine
Aplastic Anemia, Cytopenia
A Study of Emapalumab for Pediatric Aplastic Anemia
The purpose of this study is to find out whether upfront emapalumab treatment can help in sAA (Aplastic Anemia) treatment planning and increase the effectiveness of standard treatment options. Funding Source- FDA OOPD
- Conditions
- Aplastic Anemia, Cytopenia, Hypocellular Marrow
- Trial name
- NCT06430788
- Testing
- Emapalumab
- Where
- 6 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Transplantation, Renal, Immunosuppression
MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression
Individuals absorb Cellcept (MMF/Mycophenolate Mofetil) at different rates and it is difficult to determine an individuals level of Mycophenolate Mofetil (MMF, trade name Cellcept)from a single measurement.
- Trial name
- NCT00187941
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Florida
Leukemia
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00066794
- Testing
- filgrastim, sargramostim, cyclosporine
- Where
- 97 sites in United States
- Volunteers
- 69 people
- Sponsor
- SWOG Cancer Research Network
Hereditary Angioedema
A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
This is an open-label, three part study to evaluate the effect of BCX7353 on drug transporters as well as the effect of an inhibitor of drug transport on BCX7353.
- Trial name
- NCT03136237
- Testing
- BCX7353, Digoxin, BCX7353 + digoxin
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I trial studies the side effects and best dose of yttrium Y 90 anti-CD45 monoclonal antibody BC8 when given together with fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell…
- Trial name
- NCT01503242
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Immune Thrombocytopenia
DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients
The project was undertaken by Qilu Hospital, Shandong University in China. In order to report the efficacy and safety of dexamethasone combined with rituximab, cyclosporin and intravenous immunoglobulin in the management of newly…
- Trial name
- NCT02834468
- Testing
- DEX Combined With RTX, CSA and IVIG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shandong University
Acute Leukemia, Myelodysplasia
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis to standard tacrolimus and methotrexate…
- Trial name
- NCT02345850
- Testing
- Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide
- Where
- 28 sites in United States
- Volunteers
- 346 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA).
- Trial name
- NCT00065260
- Testing
- Campath-1H, r-ATG, CsA
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Uveitis
Multicenter Uveitis Steroid Treatment (MUST) Trial
The purpose of this study is to compare the effectiveness of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis…
- Trial name
- MUST (NCT00132691)
- Testing
- fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 255 people
- Sponsor
- JHSPH Center for Clinical Trials
Psoriasis
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
REALIZE study will include a representative sample of 500 patients with moderate to severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label…
- Trial name
- REALIZE (NCT03757013)
- Testing
- Apremilast
- Where
- 93 sites in France
- Volunteers
- 453 people
- Sponsor
- Amgen
Graft-Versus-Host Disease
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
Ocular Graft Versus Host Disease (OGVHD) is a serious potential complication of allogeneic bone marrow transplants. The usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands…
- Trial name
- HSCT (NCT02144025)
- Testing
- Cyclosporine
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
ST Elevation Acute Myocardial Infarction
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study
Infarct size is a major determinant of vital prognosis after AMI. We recently reported that cyclosporine A, when administered immediately prior to PCI reperfusion, can significantly reduce infarct size in STEMI patients.
- Trial name
- CIRCUS II (NCT02934217)
- Testing
- Injection of Cyclosporin, Echocardiography
- Where
- France
- Volunteers
- 868 people
- Sponsor
- Hospices Civils de Lyon
Dry Eye Syndrome
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
The purpose of this study is to evaluate the safety and efficacy of FID 112903 given as an immediate treatment replacement in dry eye subjects that discontinue at least 6 months use of RESTASIS.
- Trial name
- NCT01198782
- Testing
- FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)
- Volunteers
- 48 people
- Sponsor
- Alcon Research
Bone Marrow Transplantation, AML
Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients
The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation.
- Trial name
- NCT07695571
- Volunteers
- 300 people
- Sponsor
- Yasmin medhat munir Mohamed
Aplastic Anemia
Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia
Acquired Aplastic anemia is one of the most frequent reason of bone marrow failure in East (Pakistan). The first treatment option is Allogenic Bone Marrow transplantation which is an expansive treatment option and also require a…
- Trial name
- ATG (NCT02028416)
- Testing
- ATG-fresenius
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- National Institute of Blood Disease Center, Pakistan
Bronchiolitis Obliterans, Immunosuppression
Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation
The purpose of the study is to compare efficacy and safety of two different immunosuppressive regimens for prevention of bronchiolitis obliterans syndrome (BOS) (chronic lung allograft rejection)after lung transplantation…
- Trial name
- EAILTX (NCT01429844)
- Testing
- Tacrolimus, Cyclosporine
- Where
- 14 sites in Australia, Austria and 4 more
- Volunteers
- 274 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pure Red Cell Aplasia, Acquired
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased.
- Trial name
- PRCA (NCT04470804)
- Testing
- Sirolimus, Cyclosporine A
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Bing Han
End Stage Liver Disease, Hepatitis C
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
- Trial name
- NCT00163657
- Testing
- Daclizumub, Tacrolimus, Cyclosporine
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Baylor Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.